Clinical trial
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
NCT00090194 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00090194 |
|---|---|
| Title | Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10% |
| Official title | Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Failure, Chronic |
| Intervention type | Biological |
| Interventions | Immune Globulin Intravenous (Human), 10% |
| Enrollment | 56 |
| Start date | Jun 1, 2003 |
| Completion | Mar 1, 2004 |
| First posted | Aug 26, 2004 |
| Last update posted | Jan 11, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: